Breaking News Instant updates and real-time market news.

ASH

Ashland

$80.10

0.66 (0.83%)

04:46
06/14/19
06/14
04:46
06/14/19
04:46

Ashland downgraded to Neutral from Overweight at JPMorgan

JPMorgan analyst Jeffrey Zekauskas downgraded Ashland Global Holdings to Neutral from Overweight with an unchanged price target of $82.

ASH Ashland
$80.10

0.66 (0.83%)

12/27/18
JPMS
12/27/18
UPGRADE
JPMS
Overweight
Ashland upgraded to Overweight from Neutral at JPMorgan
12/27/18
JPMS
12/27/18
UPGRADE
Target $86
JPMS
Overweight
Ashland upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jeffrey Zekauskas upgraded Ashland to Overweight from Neutral with an $86 price target, citing valuation. In a research note to investors, the analyst says he thinks the recent steep price decline in the general market presents an opportunity for a good entry point into Ashland shares, which have deceased somewhat more sharply in value than the general market over the last few weeks. Zekauskas says he does not view the recent decline in the value of Ashland as company-specific, but regards it as a function of a more risk-averse market.
04/09/19
JPMS
04/09/19
DOWNGRADE
Target $51
JPMS
Neutral
JPMorgan downgrades H.B. Fuller to Neutral on fair valuation
JPMorgan analyst Jeffrey Zekauskas downgraded H.B. Fuller (FUL) to Neutral from Overweight with an unchanged price target of $51. The analyst views the shares as valued fairly at current levels and sees better opportunity in semi-commodity peers such as Eastman Chemical (EMN), Cabot (CBT) or Ashland (ASH). He says the other names offer a higher free cash flow yield, lower leverage or lower enterprise value to EBITDA multiples. Volume growth at H.B. Fuller has slowed with the global economy, particularly in China, Europe and the United States, Zekauskas tells investors in a research note.
05/24/19
JEFF
05/24/19
NO CHANGE
Target $93
JEFF
Buy
Ashland shares have 30% upside potential in next year, says Jefferies
Jefferies analyst Laurence Alexander sees around 30% upside potential in shares of Ashland over the next year, "even in a choppy environment." A combination of "fairly resilient" end-markets, a favorable mix shift opportunity, and a multi-year tailwind from cost-cutting makes an 11 times EBITDA multiple achievable, Alexander tells investors in a research note. He raised his price target for Ashland to $93 from $90 and keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

RNG

RingCentral

$110.98

-0.185 (-0.17%)

08:35
06/27/19
06/27
08:35
06/27/19
08:35
Recommendations
RingCentral analyst commentary  »

RingCentral added as a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

PFSW

PFSweb

$3.70

-0.1 (-2.63%)

08:35
06/27/19
06/27
08:35
06/27/19
08:35
Hot Stocks
PFSweb engaged by Shiseido Americas to provide order fulfillment »

PFSweb has been engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

GES

Guess

$15.22

0.51 (3.47%)

, AEO

American Eagle

$16.98

-0.19 (-1.11%)

08:35
06/27/19
06/27
08:35
06/27/19
08:35
Recommendations
Guess, American Eagle analyst commentary  »

Jefferies reiterates Buys…

GES

Guess

$15.22

0.51 (3.47%)

AEO

American Eagle

$16.98

-0.19 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$43.00

-0.78 (-1.78%)

08:34
06/27/19
06/27
08:34
06/27/19
08:34
Hot Stocks
Zenith announces dosing of first patient in Phase 1b/2 trial with Pfizer »

Zenith Epigenetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 28

    Aug

  • 16

    Sep

DRRX

Durect

$0.70

0.0295 (4.40%)

08:33
06/27/19
06/27
08:33
06/27/19
08:33
Hot Stocks
Durect submits response to FDA's Complete Response Letter for Posimir »

Durect has submitted a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:33
06/27/19
06/27
08:33
06/27/19
08:33
General news
Jobless Claims data reported »

Week of 6/22 Jobless…

CPS

Cooper-Standard

$44.63

1.43 (3.31%)

08:33
06/27/19
06/27
08:33
06/27/19
08:33
Hot Stocks
Cooper-Standard names Aleksandra Miziolek as chief transformation officer »

Cooper Standard announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.90

0.06 (0.61%)

08:33
06/27/19
06/27
08:33
06/27/19
08:33
Initiation
Ford initiated  »

Credit Suisse bullish on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jul

  • 24

    Jul

  • 23

    Oct

EVOK

Evoke Pharma

$0.53

-0.0325 (-5.74%)

08:32
06/27/19
06/27
08:32
06/27/19
08:32
Hot Stocks
Evoke Pharma request Type A FDA meeting for resubmission of Gimoti NDA »

Evoke Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCS

OncoSec

$2.50

-0.11 (-4.21%)

08:32
06/27/19
06/27
08:32
06/27/19
08:32
Hot Stocks
OncoSec enters collaboration with Dana-Farber Cancer Institute »

OncoSec Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$48.64

-0.36 (-0.73%)

08:31
06/27/19
06/27
08:31
06/27/19
08:31
Recommendations
Esperion analyst commentary  »

Esperion funding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQBG

Sequential Brands

$0.50

-0.0049 (-0.98%)

08:30
06/27/19
06/27
08:30
06/27/19
08:30
Hot Stocks
NBA player Montrezl Harrell signs multi-year sneaker, apparel deal with AND1 »

AND1 and its newest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APEX

Apex Global Brands

$0.60

0.0999 (19.98%)

, ARVN

Arvinas

$23.38

0.93 (4.14%)

08:30
06/27/19
06/27
08:30
06/27/19
08:30
Options
Four new option listings and one option delisting on June 27th »

New option listings for…

APEX

Apex Global Brands

$0.60

0.0999 (19.98%)

ARVN

Arvinas

$23.38

0.93 (4.14%)

LOVE

Lovesac

$28.99

-0.83 (-2.78%)

PRVB

Provention Bio

$11.41

-0.805 (-6.59%)

CHKE

Cherokee

$0.60

0.0999 (19.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTV

Aptiv

$78.87

0.72 (0.92%)

08:29
06/27/19
06/27
08:29
06/27/19
08:29
Initiation
Aptiv initiated  »

Credit Suisse bullish on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEMP

Gemphire Therapeutics

$0.94

-0.26 (-21.67%)

08:28
06/27/19
06/27
08:28
06/27/19
08:28
Upgrade
Gemphire Therapeutics rating change  »

Gemphire Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$48.64

-0.36 (-0.73%)

08:27
06/27/19
06/27
08:27
06/27/19
08:27
Hot Stocks
Esperion reaches $200M revenue-based funding agreement with Oberland Capital »

Esperion and an investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$34.68

-0.99 (-2.78%)

08:27
06/27/19
06/27
08:27
06/27/19
08:27
Hot Stocks
CareDx 'applauds' progress in Medicare immunosuppressive medication legislation »

CareDx said it,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAN

Dana

$18.38

0.74 (4.20%)

08:27
06/27/19
06/27
08:27
06/27/19
08:27
Initiation
Dana initiated  »

Credit Suisse bullish on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$57.00

-1.01 (-1.74%)

08:26
06/27/19
06/27
08:26
06/27/19
08:26
Periodicals
Huawei in talks with Verizon over royalty payments for patents, CNBC reports »

Huawei is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 09

    Jul

  • 01

    Aug

DOVA

Dova Pharmaceuticals

$10.56

0.27 (2.62%)

08:25
06/27/19
06/27
08:25
06/27/19
08:25
Hot Stocks
Dova Pharmaceuticals announces FDA approval of sNDA for DOPTELET »

Dova Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 30

    Jun

WBC

Wabco

$131.95

-0.23 (-0.17%)

08:25
06/27/19
06/27
08:25
06/27/19
08:25
Conference/Events
Wabco to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

TSLA

Tesla

$219.22

-0.47 (-0.21%)

08:24
06/27/19
06/27
08:24
06/27/19
08:24
Initiation
Tesla initiated  »

Tesla initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OVID

Ovid Therapeutics

$1.79

-0.04 (-2.19%)

08:23
06/27/19
06/27
08:23
06/27/19
08:23
Hot Stocks
Ovid Therapeutics initiates Phase 3 trial of OV101 »

Ovid Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTOS

Kratos Defense

$22.20

0.35 (1.60%)

08:22
06/27/19
06/27
08:22
06/27/19
08:22
Hot Stocks
Kratos Defense receives $4.1M C5ISR system contract award »

Kratos Defense &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRCA

Verrica Pharmaceuticals

08:22
06/27/19
06/27
08:22
06/27/19
08:22
Recommendations
Verrica Pharmaceuticals analyst commentary  »

Verrica reported positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.